|
US543153A
(en)
|
|
1895-07-23 |
|
kidder |
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
US5156965A
(en)
|
1983-11-29 |
1992-10-20 |
Igen, Inc. |
Catalytic antibodies
|
|
US5229272A
(en)
|
1989-04-25 |
1993-07-20 |
Igen, Inc. |
Catalytic antibody components
|
|
US5126258A
(en)
|
1984-09-07 |
1992-06-30 |
Scripps Clinic And Research Foundation |
Molecules with antibody combining sites that exhibit catalytic properties
|
|
US5030717A
(en)
|
1986-09-17 |
1991-07-09 |
Scripps Clinic And Research Foundation |
Antibodies which catalyze hydrolysis of ester bonds
|
|
US5436153A
(en)
|
1992-12-02 |
1995-07-25 |
Sprecher; Cindy A. |
Human amyloid protein precursor homolog and Kunitz-type inhibitor
|
|
WO1994012637A2
(en)
|
1992-12-02 |
1994-06-09 |
Zymogenetics, Inc. |
Novel human amyloid protein precursor homologue and kunitz-type inhibitors
|
|
AU6942394A
(en)
|
1993-04-23 |
1994-11-21 |
Igen, Inc. |
Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies
|
|
US5602021A
(en)
|
1994-12-29 |
1997-02-11 |
Catalytic Antibodies, Inc. |
Method for generating proteolytic enzymes specific against a selected peptide sequence
|
|
US5585108A
(en)
|
1994-12-30 |
1996-12-17 |
Nanosystems L.L.C. |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
CA2224907A1
(en)
|
1995-07-25 |
1997-02-13 |
Introgene B.V. |
Methods and means for targeted gene delivery
|
|
US6265389B1
(en)
|
1995-08-31 |
2001-07-24 |
Alkermes Controlled Therapeutics, Inc. |
Microencapsulation and sustained release of oligonucleotides
|
|
US5962313A
(en)
|
1996-01-18 |
1999-10-05 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
|
|
US5858351A
(en)
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
|
DK0932417T3
(da)
|
1996-10-17 |
2003-04-14 |
Immunomedics Inc |
Non-antigent toxinkonjugat og fusionsprotein af internaliserende receptorsystem
|
|
US6372205B1
(en)
|
1997-06-11 |
2002-04-16 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs
|
|
IT1293511B1
(it)
|
1997-07-30 |
1999-03-01 |
Gentili Ist Spa |
Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
|
|
US6703488B1
(en)
|
1998-01-15 |
2004-03-09 |
Center For Molecular Medicine And Immunology |
Antibody/receptor targeting moiety for enhanced delivery of armed ligand
|
|
US6855804B2
(en)
|
1998-03-23 |
2005-02-15 |
Board Of Regents, The University Of Texas System |
Covalently reactive transition state analogs and methods of use thereof
|
|
AU761430B2
(en)
|
1998-04-02 |
2003-06-05 |
Xintela Ab |
An integrin heterodimer and a subunit thereof
|
|
WO2000022110A2
(en)
|
1998-10-09 |
2000-04-20 |
President And Fellows Of Harvard College |
Targeted proteolysis by recruitment to ubiquitin protein ligases
|
|
US20040204379A1
(en)
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
AU2001269923A1
(en)
|
2000-06-19 |
2002-01-02 |
Genzyme Corporation |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
|
WO2002020740A2
(en)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
US6649138B2
(en)
|
2000-10-13 |
2003-11-18 |
Quantum Dot Corporation |
Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US7431923B2
(en)
|
2005-01-03 |
2008-10-07 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7534429B2
(en)
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US20060210474A1
(en)
|
2000-11-29 |
2006-09-21 |
Young David S |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7442777B2
(en)
|
2000-11-29 |
2008-10-28 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
EP1474109B1
(en)
|
2001-12-21 |
2010-08-25 |
Alcon, Inc. |
Use of synthetic inorganic nanoparticles as carriers for ophthalmic drugs
|
|
WO2003057179A2
(en)
|
2002-01-11 |
2003-07-17 |
Biomarin Pharmaceutical, Inc. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
|
US7858367B2
(en)
|
2002-04-30 |
2010-12-28 |
Duke University |
Viral vectors and methods for producing and using the same
|
|
WO2004023973A2
(en)
|
2002-09-12 |
2004-03-25 |
Incyte Corporation |
Molecules for diagnostics and therapeutics
|
|
US20050142141A1
(en)
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
ES2371913T3
(es)
|
2003-01-22 |
2012-01-11 |
Duke University |
Constructos mejorados para expresar polipéptidos lisosomales.
|
|
SE0301087D0
(sv)
|
2003-04-14 |
2003-04-14 |
Cartela Ab |
New monoclonal antibody
|
|
EP1620133B1
(en)
|
2003-05-01 |
2015-12-09 |
Genzyme Corporation |
Gene therapy for neurometabolic disorders
|
|
US20040258666A1
(en)
|
2003-05-01 |
2004-12-23 |
Passini Marco A. |
Gene therapy for neurometabolic disorders
|
|
CA2529659A1
(en)
|
2003-06-18 |
2004-12-29 |
Ulrich Haupts |
Engineered proteolytic enzyme with altered specificity determining regions
|
|
US7371539B2
(en)
|
2003-12-03 |
2008-05-13 |
President And Fellows Of Harvard College |
Targeted polypeptide degradation
|
|
US20080014188A1
(en)
|
2004-02-06 |
2008-01-17 |
Zankel Todd C |
Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
|
|
CA2553955C
(en)
|
2004-02-10 |
2012-08-28 |
Zystor Therapeutics, Inc. |
Acid alpha-glucosidase and fragments thereof
|
|
WO2005077333A2
(en)
|
2004-02-10 |
2005-08-25 |
University Of Florida Research Foundation, Inc. |
Gel-based delivery of recombinant adeno-associated virus vectors
|
|
EP1732599A4
(en)
|
2004-03-25 |
2008-05-14 |
Centocor Inc |
USE OF EMMPRINE ANTAGONISTS FOR THE TREATMENT OF DISEASES RELATED TO EXCESSIVE ANGIOGENESIS
|
|
US20060171926A1
(en)
|
2004-04-30 |
2006-08-03 |
Passini Marco A |
Gene therapy for neurometabolic disorders
|
|
JP5136766B2
(ja)
|
2004-12-15 |
2013-02-06 |
ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
キメラベクター
|
|
EP1877099B1
(en)
|
2005-04-06 |
2012-09-19 |
Genzyme Corporation |
Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
|
|
JP5829372B2
(ja)
|
2005-05-02 |
2015-12-09 |
ジェンザイム・コーポレーション |
神経代謝性疾患のための遺伝子治療
|
|
CN102016814B
(zh)
|
2005-06-17 |
2013-10-23 |
北卡罗来纳大学查珀尔希尔分校 |
纳米粒子制备方法、系统及材料
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
SG153825A1
(en)
|
2005-12-16 |
2009-07-29 |
Ibc Pharmaceuticals Inc |
Multivalent immunoglobulin-based bioactive assemblies
|
|
CA2641070C
(en)
|
2006-02-06 |
2017-01-03 |
Ramot At Tel-Aviv University Ltd. |
Enzyme replacement therapy for treating lysosomal storage diseases
|
|
JP5307708B2
(ja)
|
2006-06-02 |
2013-10-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒトｉｌ−６受容体に対する高親和性抗体
|
|
US20080089891A1
(en)
|
2006-07-26 |
2008-04-17 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
|
GB0615662D0
(en)
|
2006-08-07 |
2006-09-13 |
Affitech As |
Antibody
|
|
AR064801A1
(es)
|
2006-08-18 |
2009-04-29 |
Xoma Technology Ltd |
Anticuerpo especifico prlr (receptor de prolactina) y sus usos
|
|
EP2099523A2
(en)
|
2006-11-13 |
2009-09-16 |
ZyStor Therapeutics , Inc. |
Methods for treating pompe disease
|
|
EP2132309A4
(en)
|
2007-02-23 |
2011-01-05 |
Univ Florida |
COMPOSITIONS AND METHODS OF TREATING GLYCOLOGICAL MEMORY DISEASES
|
|
US20120322861A1
(en)
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
WO2008143354A1
(ja)
|
2007-05-18 |
2008-11-27 |
Tokyo Metropolitan Organization For Medical Research |
酵素補充療法用医薬組成物
|
|
AU2008282496B2
(en)
|
2007-07-27 |
2013-04-04 |
Armagen Technologies, Inc. |
Methods and compositions for increasing alpha-iduronidase activity in the CNS
|
|
WO2009075815A1
(en)
|
2007-12-07 |
2009-06-18 |
Duke University |
Immunomodulating gene therapy
|
|
US8420620B2
(en)
|
2008-01-24 |
2013-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Induced internalization of surface receptors
|
|
CA2722238C
(en)
|
2008-04-22 |
2017-11-28 |
Life Sciences Research Partners Vzw |
Liver-specific nucleic acid regulatory elements and methods and use thereof
|
|
JP5627571B2
(ja)
|
2008-05-07 |
2014-11-19 |
バイオマリン ファーマシューティカル インコーポレイテッド |
リソソーム標的化ペプチドおよびその使用
|
|
CN102316898A
(zh)
|
2008-09-29 |
2012-01-11 |
森托科尔奥索生物科技公司 |
抗cd147抗体、方法和用途
|
|
EP3130607B1
(en)
*
|
2008-10-06 |
2024-04-17 |
Minerva Biotechnologies Corporation |
Muc1* antibodies
|
|
EP2241576A1
(en)
|
2009-04-17 |
2010-10-20 |
Trion Pharma Gmbh |
Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells
|
|
EP3679942A1
(en)
|
2009-06-17 |
2020-07-15 |
BioMarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
MY192182A
(en)
|
2009-06-26 |
2022-08-04 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
KR101498098B1
(ko)
|
2009-07-01 |
2015-03-03 |
케메트 일렉트로닉스 코포레이션 |
고전압 성능을 가지는 고캐패시턴스 다층레이어
|
|
CA2769670C
(en)
|
2009-07-31 |
2018-10-02 |
Ethris Gmbh |
Rna with a combination of unmodified and modified nucleotides for protein expression
|
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
|
EP2332995A1
(en)
|
2009-12-10 |
2011-06-15 |
Bayer Schering Pharma Aktiengesellschaft |
Neutralizing prolactin receptor antibodies and their therapeutic use
|
|
WO2011112566A2
(en)
|
2010-03-11 |
2011-09-15 |
Abbott Laboratories |
Basigin binding proteins
|
|
WO2011140279A1
(en)
|
2010-05-04 |
2011-11-10 |
Wayne State University |
Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
|
|
WO2011139379A2
(en)
|
2010-05-06 |
2011-11-10 |
Duke University |
A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
|
|
US9347050B2
(en)
|
2010-09-29 |
2016-05-24 |
Oxyrane Uk Limited |
Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
|
|
US8679478B2
(en)
|
2010-10-04 |
2014-03-25 |
Duke University |
Methods of lysosomal storage disease therapy
|
|
US9782342B2
(en)
|
2010-10-11 |
2017-10-10 |
Wichita State University |
Composite magnetic nanoparticle drug delivery system
|
|
ES2829199T3
(es)
|
2010-11-22 |
2021-05-31 |
Amicus Therapeutics Inc |
Nuevas secuencias de señalización para mejorar la expresión y segregación de proteínas de enzimas recombinantes y otras proteínas
|
|
CA2818173C
(en)
|
2010-11-30 |
2022-05-03 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
|
ME02106B
(me)
|
2011-02-25 |
2015-10-20 |
Regeneron Pharma |
Miševi sa adam6
|
|
CN103443273B
(zh)
|
2011-03-16 |
2016-10-26 |
天野酶制品株式会社 |
修饰型α-葡萄糖苷酶及其用途
|
|
WO2012125987A2
(en)
|
2011-03-17 |
2012-09-20 |
Massachusetts Institute Of Technology |
Delivery system
|
|
WO2012135857A1
(en)
|
2011-03-31 |
2012-10-04 |
University Of Iowa Research Foundation |
Methods and compositions for treating brain diseases
|
|
WO2012136519A1
(en)
|
2011-04-06 |
2012-10-11 |
Bayer Pharma Aktiengesellschaft |
Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
|
|
MX2013012345A
(es)
|
2011-04-22 |
2015-05-07 |
Genzyme Corp |
Alfa glucosidasa acida modificada con procesamiento acelerado.
|
|
US20120283503A1
(en)
|
2011-04-29 |
2012-11-08 |
The Johns Hopkins University |
Nanoparticle loaded stem cells and their use in mri guided hyperthermia
|
|
HRP20180291T1
(hr)
|
2011-05-27 |
2018-03-23 |
Amicus Therapeutics, Inc. |
Postupci za sparivanje ciljajućeg peptida na rekombinantne lizosomalne enzime za poboljšano liječenje lizosomskih bolesti nakupljanja
|
|
EP2530089A1
(en)
|
2011-06-03 |
2012-12-05 |
Bayer Pharma Aktiengesellschaft |
Neutralising prolactin receptor antibody Mat3 and its therapeutical use
|
|
BR112014012590A8
(pt)
|
2011-11-23 |
2017-12-19 |
Igenica Inc |
Anticorpos anti-cd98 e métodos de uso dos mesmos
|
|
AU2012346448B2
(en)
|
2011-12-02 |
2017-09-14 |
Armagen, Inc. |
Methods and compositions for increasing arylsulfatase A activity in the CNS
|
|
SG10201605675WA
(en)
|
2011-12-20 |
2016-09-29 |
Regeneron Pharma |
Humanized light chain mice
|
|
EP2825553B1
(en)
|
2012-03-14 |
2018-07-25 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules and uses thereof
|
|
KR20150020250A
(ko)
|
2012-06-19 |
2015-02-25 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
당뇨병을 치료하기 위한 조성물 및 방법
|
|
EP3196301B1
(en)
|
2012-07-11 |
2018-10-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of monogenic diseases
|
|
HUE045144T2
(hu)
|
2012-08-29 |
2019-12-30 |
Hoffmann La Roche |
Véragygát-shuttle
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
ES2729997T3
(es)
|
2012-11-27 |
2019-11-07 |
Biomarin Pharm Inc |
Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
|
|
WO2014130722A1
(en)
|
2013-02-20 |
2014-08-28 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of forbes-cori disease
|
|
AU2014218854B2
(en)
|
2013-02-20 |
2019-01-24 |
Valerion Therapeutics, Llc |
Methods and compositions for treatment of Pompe disease
|
|
TW201513882A
(zh)
|
2013-03-15 |
2015-04-16 |
Bayer Healthcare Llc |
抗－催乳激素受體抗體調配物
|
|
CN115120746A
(zh)
|
2013-05-15 |
2022-09-30 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
WO2014185908A2
(en)
|
2013-05-15 |
2014-11-20 |
The Translational Genomics Research Institute |
Hybridoma clones, monoclonal antibodies, and methods of use
|
|
EP3594240B1
(en)
*
|
2013-05-20 |
2023-12-06 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
|
US9388243B2
(en)
|
2013-05-29 |
2016-07-12 |
Samsung Electronics Co., Ltd. |
Method of target membrane protein depletion
|
|
WO2015009961A1
(en)
|
2013-07-19 |
2015-01-22 |
Armagen Technologies, Inc. |
Compositions and methods related to structures that cross the blood brain barrier
|
|
EP3024497B1
(en)
|
2013-07-26 |
2021-01-13 |
University of Iowa Research Foundation |
Methods and compositions for treating brain diseases
|
|
TWI641620B
(zh)
|
2013-08-21 |
2018-11-21 |
再生元醫藥公司 |
抗－ｐｒｌｒ抗體及其用途
|
|
US9545451B2
(en)
|
2013-08-21 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
|
|
CN105899540B
(zh)
|
2014-01-03 |
2020-02-07 |
豪夫迈·罗氏有限公司 |
双特异性抗-半抗原/抗-血脑屏障受体的抗体、其复合物及它们作为血脑屏障穿梭物的应用
|
|
CA2932547C
(en)
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
|
US9629801B2
(en)
|
2014-01-10 |
2017-04-25 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
|
PL3097197T3
(pl)
|
2014-01-21 |
2021-06-28 |
Vrije Universiteit Brussel |
Mięśniowo-specyficzne elementy regulatorowe kwasów nukleinowych oraz sposoby i ich zastosowanie
|
|
JP2017114763A
(ja)
|
2014-03-26 |
2017-06-29 |
第一三共株式会社 |
抗ｃｄ９８抗体−薬物コンジュゲート
|
|
US9951141B2
(en)
|
2014-06-02 |
2018-04-24 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates, their preparation and their therapeutic use
|
|
CN106604934A
(zh)
|
2014-06-11 |
2017-04-26 |
分子模板公司 |
耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
|
|
WO2016044947A1
(en)
|
2014-09-26 |
2016-03-31 |
Exerkine Corporation |
Exosomes useful to treat lysosomal storage disease
|
|
WO2016065319A1
(en)
|
2014-10-24 |
2016-04-28 |
Shire Human Genetic Therapies, Inc. |
Lysosomal targeting of enzymes, and uses thereof
|
|
EP3218411B1
(en)
*
|
2014-11-14 |
2022-01-12 |
Ossianix, Inc. |
Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
|
|
US10508151B2
(en)
|
2014-11-19 |
2019-12-17 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
MA41022A
(fr)
*
|
2014-11-24 |
2017-10-03 |
Shire Human Genetic Therapies |
Ciblage lysosomial et utilisations correspondantes
|
|
KR20170085595A
(ko)
|
2014-12-10 |
2017-07-24 |
제넨테크, 인크. |
혈뇌 장벽 수용체 항체 및 사용 방법
|
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
EA039366B1
(ru)
|
2015-06-24 |
2022-01-19 |
Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. |
Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
|
|
HUE057952T2
(hu)
|
2015-06-24 |
2022-06-28 |
Hoffmann La Roche |
Anti-transzferrin receptor antitestek testreszabott affinitással
|
|
IL296285A
(en)
|
2015-07-06 |
2022-11-01 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
WO2017026497A1
(ja)
|
2015-08-10 |
2017-02-16 |
国立大学法人大阪大学 |
抗体
|
|
EP3356415B1
(en)
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr inhibitors for reduzing cholesterol levels
|
|
TWI873952B
(zh)
|
2015-10-02 |
2025-02-21 |
瑞士商赫孚孟拉羅股份公司 |
雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
KR102738860B1
(ko)
|
2015-10-23 |
2024-12-04 |
유니버시티 오브 아이오와 리써치 파운데이션 |
리소좀 축적 질환 (lsd)을 갖는 포유동물의 치료 방법에 사용하기 위한 aav 입자를 포함하는 약제학적 조성물
|
|
DK3386534T3
(da)
|
2015-12-08 |
2020-11-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
US10233252B2
(en)
|
2015-12-21 |
2019-03-19 |
Wisconsin Alumni Research Foundation |
pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
|
|
KR20250007693A
(ko)
|
2015-12-30 |
2025-01-14 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
폼페병 치료용의 강화된 산 알파-글루코시다제
|
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
|
KR20260018979A
(ko)
|
2016-02-05 |
2026-02-09 |
젠맵 에이/에스 |
개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
|
|
AU2017239641A1
(en)
|
2016-03-30 |
2018-10-18 |
Amicus Therapeutics, Inc. |
Formulations comprising recombinant acid alpha-glucosidase
|
|
EP3448891A1
(en)
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
CN105820250B
(zh)
|
2016-04-29 |
2019-04-30 |
中国人民解放军第四军医大学 |
一种抗basigin人源化抗体及其应用
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
JP2019524651A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗ｃｄ９８抗体及び抗体薬物コンジュゲート
|
|
US20200147235A1
(en)
|
2016-06-08 |
2020-05-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
WO2017214462A2
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
EP3494216B1
(en)
|
2016-08-06 |
2025-10-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
EP3293203A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
WO2018046774A1
(en)
|
2016-09-12 |
2018-03-15 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
CA3041548A1
(en)
|
2016-11-04 |
2018-05-11 |
The Children's Hospital Of Philadelphia |
Gene transfer compositions, methods and uses for treating neurodegenerative diseases
|
|
EP3548514A1
(en)
|
2016-11-29 |
2019-10-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prlr positive breast cancer
|
|
KR102497564B1
(ko)
|
2016-12-26 |
2023-02-07 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
|
|
ES2870776T3
(es)
|
2017-01-27 |
2021-10-27 |
Xintela Ab |
Prevención y tratamiento de daños o enfermedades de los huesos y cartílagos
|
|
WO2018165619A1
(en)
|
2017-03-09 |
2018-09-13 |
Cytomx Therapeutics, Inc. |
Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
|
|
SMT202300187T1
(it)
|
2017-05-15 |
2023-07-20 |
Amicus Therapeutics Inc |
Alfa-glucosidasi acida umana ricombinante
|
|
WO2018210898A1
(en)
|
2017-05-18 |
2018-11-22 |
F. Hoffmann-La Roche Ag |
Reduction of application-related side reaction of a therapeutic antibody
|
|
DK3635009T3
(da)
|
2017-06-07 |
2026-03-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
US20210128728A1
(en)
|
2017-07-10 |
2021-05-06 |
Bayer Pharma Aktiengesellschaft |
Prolactin receptor antibody for male and female pattern hair loss
|
|
RU2770922C2
(ru)
|
2017-09-20 |
2022-04-25 |
4Д Молекьюлар Терапьютикс Инк. |
Капсиды вариантов аденоассоциированных вирусов и методы их применения
|
|
PL3691692T3
(pl)
|
2017-10-14 |
2021-07-19 |
Abbvie Inc. |
Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania
|
|
CN111936621B
(zh)
|
2018-02-05 |
2025-05-13 |
奥登茨治疗公司 |
转录调控元件和它的用途
|
|
IL276327B2
(en)
|
2018-02-05 |
2024-05-01 |
Japan Chem Res |
Method for delivering drug to muscle
|
|
US12258597B2
(en)
|
2018-02-07 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for therapeutic protein delivery
|
|
EP3765062A4
(en)
|
2018-03-15 |
2022-04-13 |
Valerion Therapeutics, LLC |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYGLUCOUS DISORDERS
|
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
|
MY207355A
(en)
|
2018-05-16 |
2025-02-21 |
Spark Therapeutics Inc |
Codon-optimized acid lpha-glucosidase expression cassettes and methods of using same
|
|
BR112020023145A2
(pt)
|
2018-05-17 |
2021-02-02 |
Regeneron Pharmaceuticals, Inc. |
anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
|
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
US20210317226A1
(en)
|
2018-08-02 |
2021-10-14 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
BR112021003399A2
(pt)
|
2018-08-24 |
2021-05-18 |
Spark Therapeutics, Inc. |
sequências de promotores otimizadas, construtos de expressão livres de íntron e métodos de uso
|
|
JP2022513067A
(ja)
|
2018-11-16 |
2022-02-07 |
アスクレピオス バイオファーマシューティカル， インコーポレイテッド |
ポンペ病を処置するための治療用アデノ随伴ウイルス
|
|
KR20220022107A
(ko)
|
2018-12-05 |
2022-02-24 |
아베오나 테라퓨틱스 인코퍼레이티드 |
유전자 전달을 위한 재조합 아데노-연관 바이러스 벡터
|
|
CA3124790A1
(en)
|
2019-01-09 |
2020-07-16 |
Vect-Horus |
Transferrin receptor-binding molecules, conjugates thereof and their uses
|
|
WO2020163480A1
(en)
|
2019-02-05 |
2020-08-13 |
Amicus Therapeutics, Inc. |
Recombinant human acid alpha-glucosidase and uses thereof
|
|
JP7585233B2
(ja)
|
2019-04-30 |
2024-11-18 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ポンペ病の治療のために有用な組成物
|
|
EP3996696A1
(en)
|
2019-07-09 |
2022-05-18 |
Genethon |
Treatment of glycogen storage disease (gsd)
|
|
TW202346348A
(zh)
|
2022-01-10 |
2023-12-01 |
美商再生元醫藥公司 |
作為基因治療所遞送之bbb靶向的gaa在龐貝氏症小鼠模型中治療cns及肌肉
|